The latest price target for Biodexa Pharmaceuticals (NASDAQ:BDRX) was reported by Ladenburg Thalmann on February 8, 2024. The analyst firm set a price target for $8.00 expecting BDRX to rise to within 12 months (a possible 92.31% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodexa Pharmaceuticals (NASDAQ:BDRX) was provided by Ladenburg Thalmann, and Biodexa Pharmaceuticals initiated their buy rating.

There is no last upgrade for Biodexa Pharmaceuticals

There is no last downgrade for Biodexa Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodexa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodexa Pharmaceuticals was filed on February 8, 2024 so you should expect the next rating to be made available sometime around February 8, 2025.

While ratings are subjective and will change, the latest Biodexa Pharmaceuticals (BDRX) rating was a initiated with a price target of $0.00 to $8.00. The current price Biodexa Pharmaceuticals (BDRX) is trading at is $4.16, which is within the analyst’s predicted range.